05:11pm Friday 22 September 2017

Scientists develop new drug treatment for malaria

The new drug is made from simple organic molecules

As part of the £1.5 million project, researchers are now testing the drug to determine how the treatment could progress to clinical trials.  The drug is made from simple organic molecules and will be cheaper   to mass produce compared to existing therapies.

Malaria is the world’s most deadly parasitic infection, resulting in nearly one million deaths a year.  The team at Liverpool have created a synthetic drug based on the chemical structure of artemisinin, an extract of a Chinese herb commonly used in malaria treatment.  The new drug, which can be taken orally, is more potent than naturally derived artemisinin.

Artemisinin is known to interact with a substance inside parasite-infected red blood cells, causing a chain of events that destroys malaria.  The treatment, however, is difficult to mass produce and can be chemically unstable in the body.  Scientists have now found a way of creating the most reactive part of artemisinin synthetically and fusing it with a cage-like structure made of organic molecules to make the drug more chemically stable.  The stability of the chemical structure in the body makes the drug last longer, reducing the chance of the parasite reappearing.

Professor Paul O’Neill, from the University’s Department of Chemistry, explains: “Malaria affects the world’s poorest countries and hospitals are unable to afford expensive treatments.  The problem with current artemisinin-based therapies is their limited availability, poor oral absorption and high cost. We have created a new drug that is easily absorbed by the body, chemically stable and highly potent.  It is made from very simple organic materials and therefore will be more cost-effective to mass produce than current therapies.”

The research is funded by the European Commission and published in Angewandte Chemie Int Ed.

Notes to editors:

1.  The University of Liverpool is a member of the Russell Group of leading research-intensive institutions in the UK. It attracts collaborative and contract research commissions from a wide range of national and international organisations valued at more than £98 million annually.

Contact us:

Kate Spark

Head of Public Relations

Phone: work +44 (0) 151 794 2247
Out of hours (cell+44 (0) 7970 247391)

Samantha Martin

Senior Press Officer

Phone: work +44 (0) 151 794 2248
Out of hours (cell+44 (0) 7973 247836)

Sarah Stamper

Press and Marketing Officer

Phone: work +44 (0) 151 794 3044
Out of hours (cell+44 (0) 7970 247396)


Share on:
or:

MORE FROM Medical Breakthroughs

Health news